Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience Peter T. W. Kim, MD, Srinath Chinnakotla, MD, Gary Davis, MD, Linda W. Jennings, PhD, Greg J. McKenna, MD, Nicholas Onaca, MD, Richard M. Ruiz, MD, Robert Goldstein, MD, Marlon F. Levy, MD, and Göran B. Klintmalm, MD, PhD Different renal-sparing immunosuppressive protocols have been used in liver transplantation. At our institution, muromonab-CD3 (OKT3) is used in patients with acute renal failure (ARF), along with a delay in starting a calcineurin inhibitor. This study was conducted to compare outcomes in liver transplant patients with ARF who received OKT3 and those who did not. From 1988 to 2007, ARF was present in 1685 of 2587 patients (65%). OKT3 was used in 109 patients (OKT3 group). The control group (1416 patients) received a low-dose calcineurin inhibitor. The OKT3 group was more critically ill. In spite of this, the OKT3 group patients who were on renal replacement therapy (RRT) achieved long-term survival similar to that of the control group on RRT. Among the patients who were not on RRT, the OKT3 group had a higher complete recovery rate, but this did not translate into improved long-term survival. Bacterial and fungal infections were more common in the OKT3 group; however, there was no increased risk of malignancy or death from hepatitis C recurrence. The use of OKT3 in patients with ARF allowed more critically ill patients on RRT to achieve survival rates similar to those of patients who did not receive OKT3.
A cute renal failure (ARF), also known as acute kidney injury, has been reported to occur in 14% to 94% of patients after liver transplantation (1) (2) (3) (4) (5) (6) (7) . Such a wide range is attributed to the lack of a uniform defi nition of ARF. Th e risk factors for ARF include preexisting renal dysfunction, diabetes mellitus, extensive intraoperative blood loss, postoperative infection, and calcineurin inhibitor (CNI) nephrotoxicity. In addition to its inherent morbidity, ARF is a known risk factor for chronic kidney disease in liver transplant patients and is associated with decreased long-term survival (7, 8) . Th e incidence of chronic kidney disease in liver transplant patients can be as high as 18% at 5 years (9) . A recent study from our institution showed a higher incidence of sepsis and cardiovascular events in patients with ARF, providing a possible explanation for the decreased long-term survival in these patients (7) .
Several factors may precipitate ARF in the posttransplant period. CNI nephrotoxicity plays a major role. Diff erent CNIsparing immunosuppressive regimens have been employed after liver transplantation to minimize further renal injury and to promote renal recovery. At our institution, muromonab-CD3 (OKT3) (Orthoclone, Ortho Biotech, Horsham, PA), a murine monoclonal antibody, is used as a renal-sparing protocol in the early postoperative period for patients with severe ARF. Th e aims of the study were 1) to review our institution's pattern of OKT3 use in patients with severe ARF; 2) to determine the potential benefi ts of OKT3 in renal recovery in the postoperative period; 3) to determine the impact on long-term survival and potential drawbacks associated with OKT3 use; and 4) to determine an optimal dose of OKT3 for renal recovery.
PATIENTS AND METHODS Study design
Th is retrospective cohort study was conducted from the data obtained from the patient charts and from a prospectively maintained liver transplant database at the Simmons Transplant Institute. Th is study was approved by the institutional review board. Th e study was designed to compare outcomes between liver transplant patients with ARF who received OKT3 (treatment group) and those who did not (control group).
Inclusion and exclusion criteria
All patients who received primary liver transplantation at the Simmons Transplant Institute from 1988 to 2007 who had ARF were considered for the study. Th e patients who experienced ARF after retransplantation were excluded. Th e defi nition of ARF was adopted from the RIFLE criteria set by the acute dialysis qualitative initiative (10) . Acute renal failure was defi ned as 1) preoperative creatinine (Cr) >1.5 times the baseline or 1.5 mg/dL (preoperative value obtained on the day of the operation); 2) postoperative Cr >1.5 times the baseline or 1.5 mg/ dL; 3) postoperative glomerular fi ltration rate (GFR) <1.5 times the baseline value; or 4) a need for renal replacement therapy (RRT) (hemodialysis or continuous veno-veno hemodialysis) in the perioperative period (both preoperative and postoperative). Th e GFR was measured by Glofi l-125 (sodium iodothalamate I-125) clearance. Th e treatment group was defi ned as patients who received OKT3 and a delay of CNI introduction while on OKT3. OKT3 was started at the discretion of the transplant surgeon and was administered to patients who had 1) the need for pretransplant RRT; 2) the need for posttransplant RRT; or 3) oliguric ARF posttransplant, defi ned as <400 cc per day of urine output for >48 hours. Th e control group was defi ned as all other liver transplant patients with ARF after their fi rst liver transplant who did not receive OKT3 but were treated with low-dose CNI in the postoperative period.
A total of 2587 liver transplants were performed in the study period, and 1685 patients (65%) had ARF after transplant. Forty-three patients were excluded because they received OKT3 for reasons other than renal-sparing induction or they received other antibody therapy (e.g., Th ymoglobulin) for renal preservation. Th e patients who received combined liver and kidney transplantation were also excluded, since their pattern of recovery from renal dysfunction would be diff erent from that of patients who had ARF associated with liver transplantation alone. For the study, the control group consisted of 1416 patients and the OKT3 group consisted of 109 patients.
Administration of OKT3
OKT3 was given as an intravenous push at 5 mg per day on consecutive days. The therapy was monitored by absolute lymphocyte counts. The cumulative total dose was expressed as total dose in mg. The duration of therapy was determined by renal recovery at the discretion of the transplant surgeon. OKT3 therapy was stopped and a CNI was introduced when the patient displayed clinical parameters consistent with renal recovery, as defined by urine output >50 cc per hour and a decrease in serum Cr. The patients received cytomegalovirus (CMV) prophylaxis regardless of donor and recipient CMV status, with 2 to 5 mg/kg of intravenous ganciclovir daily, which was adjusted for renal dysfunction. The median cumulative dose was 50 mg (range, 20-80 mg), with a median duration of therapy of 10 days (range, 4-14 days).
Clinical endpoints
Four clinical endpoints were analyzed: 1) rates of renal function recovery; 2) incidence of acute cellular rejection; 3) incidence of infectious complications (bacterial, viral, and fungal); and 4) patient survival. Th e defi nition of renal recovery was adopted from the RIFLE criteria (10) . For patients who were on RRT such as hemodialysis or continuous veno-veno hemodialysis before or after liver transplant, independence from these modalities was defi ned as a complete recovery. For patients who did not receive RRT, a complete recovery was defi ned as a return of serum Cr to a level <1.5 times their baseline value. Partial recovery was defi ned as a Cr level >1.5 times their baseline value. Th e patient was considered to have no renal recovery if he or she did not become independent from RRT, died in the early postoperative course while on RRT, or received a kidney transplant. GFR values were analyzed at evaluation for liver transplant and at 3 months, 1 year, 2 years, and 5 years after liver transplantation.
Statistics
Statistical analysis was performed using SAS software, version 9.1.3 (SAS Institute, Cary, NC). Categorical data were analyzed with Fisher's exact test for 2 × 2 tables and the chi-square test for larger tables. Continuous variables were reported as median values with ranges and analyzed with the Wilcoxon two-sample test. Patient survival was estimated using the Kaplan-Meier method and compared using the log rank test. P values <0.05 were considered signifi cant.
RESULTS

Demographics
Th e demographic data for the control and OKT3 groups are illustrated in Table 1 . Th e OKT3 group patients were younger, had signifi cantly higher Model for End-Stage Liver Disease (MELD) scores (33 vs. 17, P < 0.0001), received more blood products, and had longer hospital and intensive care unit stays. Also, a higher proportion of patients in the OKT3 group were dependent on RRT posttransplant (38.5% vs. 6.6%, P < 0.0001). Overall, the patients in the OKT3 group were more critically ill than the patients in the control group. Th is was true when the patients were further divided into those who had RRT around the transplant and those who did not have RRT (Table 2) .
Renal recovery
Th e renal recovery in the patients who had RRT was analyzed separately from that of patients who did not have RRT. As illustrated in Table 3 , in patients who had RRT around the time of transplant, the 1-month, 6-month, and 1-year renal recovery rates were no diff erent between the control and OKT3 groups. Th e serum Cr values at the same time points refl ect a similar pattern. Th e postoperative GFR values at 3 months, 1 year, 2 years, and 5 years were not statistically diff erent between the two groups. In patients who did not have RRT around the time of transplant, the use of OKT3 appeared to result in signifi cantly higher complete renal recovery rates at 1 month, 6 months, and 1 year. Th is was refl ected by signifi cantly lower serum Cr values at 1 month in the OKT3 group (1.3 vs. 1.5 mg/dL). Th is was a signifi cant improvement, in that the same group of patients had signifi cantly higher preoperative serum Cr values (1.9 vs. 1.1 mg/ dL) (P = 0.0001). Th e long-term renal function as reported by GFR was no diff erent between the two groups at 1 year, 2 years, and 5 years posttransplant. In addition, although the 6-month and 1-year renal recovery rates were signifi cantly higher in the OKT3 group, the serum Cr and GFR did not refl ect this diff erence. Of the patients who were on RRT, 75% of the patients in the control group and 83% of the patients in the OKT3 group recovered from this modality (P = 0.4). Figure 1 illustrates the precipitous drop in Cr with OKT3 use.
Rejection, infections, and malignancies
As illustrated in Table 4 , there was no diff erence in the acute cellular rejection rates in the fi rst year between the two groups. Overall, the incidence of fungal infections was signifi cantly higher in the OKT3 group. Among the patients who had RRT, almost half of the patients in the OKT3 group were aff ected by fungal infections (47.6%). A similar pattern was observed among the patients who did not have RRT, where 43% of patients in the OKT3 group had fungal infections. Among the patients who had RRT, there was no diff erence in the bacterial, viral, and CMV infection rates between the control group and the OKT3 group. Th ere was a higher incidence of bacterial infections in the OKT3 group among the patients who did not have RRT (62% vs. 41%, P = 0.002). In addition, there was no diff erence between the two groups in 1) viral and CMV infections, 2) de novo malignancies, 3) posttransplant lymphoproliferative disorders, and 4) death from hepatitis C recurrence. Table 5 illustrates the relationship between the rates of renal recovery and cumulative doses of OKT3 administered. In the fi rst month, the highest rate of complete recovery was achieved in the group of patients who received 45 to 50 mg of OKT3, and this correlated to 9 to 10 doses when given as 5 mg per day. After the fi rst month, the highest rate of complete recovery was observed in the group of patients who received 35 to 40 mg of OKT3.
Renal recovery and OKT3 doses
Immunosuppression in the first year
At the fi rst-year mark, all the patients were on a CNI. Cyclosporine was more commonly used than tacrolimus in the control group (55% vs. 41%), whereas in the OKT3 group, tacrolimus was more commonly used (59% vs. 45%; P = 0.004).
Survival
Median follow-up was 85.5 months (range, 0.03-299 months). Th e overall long-term patient survival was higher in the control group than in the OKT3 treatment group (P = 0.03). As shown in Figure 2a , there was a signifi cant diff erence in survival between control group patients who did not have RRT and OKT3 patients who did not have RRT, but there was not a signifi cant diff erence in survival between the two groups for those who had RRT. Recovery from RRT was an important predictor of longterm survival, as illustrated in Figure 2b . In both the control and the OKT3 groups, the patients who recovered from RRT had a signifi cantly better long-term survival than those who did not (P < 0.0001).
DISCUSSION
Th e acute renal failure rate of 65% in this study underscores the magnitude of this important problem. Th e patients who received OKT3 had more severe preoperative and postoperative renal failure and were more critically ill. Th is is consistent with the pattern of practice in our institution, in which the patients who are considered to have severe ARF are selected to have a CNI-free period with OKT3 as the backbone of their immunosuppression. In keeping with this, the OKT3 group had more risk factors for ARF: more severe preoperative renal failure, higher preoperative bilirubin, more blood products during the operation, longer intensive care unit stay, and higher rates of fungal and bacterial infections. In spite of this, a higher rate of complete renal recovery was achieved in this group. Th is regimen with OKT3 allows the patients to recover from their renal failure while avoiding additional nephrotoxicity from CNI.
Although the CNI nephrotoxicity from vasoconstriction of the glomerular arterioles can be reversed, it is more pronounced in the setting of other clinical parameters that predispose the patient to ARF (11) . Conditions such as volume depletion, as well as aggressive diuretic therapy which is very common after liver transplant, may potentiate CNI nephrotoxicity (11) . OKT3 allows total avoidance of such injury by CNI and results in an improvement of renal function in patients who need optimal conditions for their renal recovery. A similar pattern of improved renal function was observed with Th ymoglobulin (12, 13) , alemtuzumab (14) , basiliximab (15) , and a combination of daclizumab and mycophenolate mofetil (16) .
A growing body of literature exists on perioperative renal failure in liver transplant, but there has been no study that focuses on renal recovery. Previously published studies focused on the risk factors for development of ARF after liver transplantation and identified preoperative Cr >1.2 mg/dL and baseline GFR <70 mL/min/1.73 m 2 as independent predictors of end-stage renal disease (17) . In addition, a higher volume of blood transfused, liver allograft dysfunction (primary nonfunction), higher bilirubin levels, and bacterial infections were identifi ed as risk factors for ARF and resulted in a higher mortality rate (2, 8, (18) (19) (20) (21) (22) . In our study, a higher rate of complete renal recovery was achieved with an OKT3-based regimen in patients who were not on RRT. Once the patients had ARF severe enough to require RRT, there was no benefi t in renal recovery with the OKT3 regimen. Th e fact that the factors contributing to renal recovery are multiple may be a possible explanation. Once the patient is already on RRT, the role nephrotoxic immunosuppression plays in ARF may be small relative to other factors. Although OKT3 did not result in improved renal recovery compared with the control group in patients who had RRT, it allowed the patients with higher MELD scores (median MELD 34) to achieve survival that was comparable to that of patients with lower MELD scores (median MELD 26) .
If the patients were not on RRT, the CNI-free period with OKT3 coverage resulted in a signifi cantly better complete renal recovery rate. Th is did not translate into an improvement in survival in this group of patients. Th e potential benefi t in survival with the OKT3 group may have been negated by other factors in that group associated with worse survival. Th e OKT3 group had signifi cantly higher MELD scores and rates of sepsis (bacterial and fungal).
Among the patients who were on RRT, recovery from RRT (i.e., independence of this modality) was the major determining factor in long-term survival. Th ere was a dramatic diff erence between the patients who were off RRT compared with the patients who were not, as illustrated in Figure 2b . Th is underscores the importance of optimizing the conditions postoperatively to allow for renal recovery so as to avoid chronic renal failure and to achieve long-term survival.
Acute renal failure after liver transplantation in combination with other factors such as CNI use, preoperative diabetes, requirement for RRT, and Cr >1.7 mg/dL preoperatively have been associated with development of end-stage renal disease Figure 1 . Renal recovery after liver transplant as illustrated by a change in serum creatinine in (a) the subgroups receiving renal replacement therapy and (b) the subgroups not on renal replacement therapy. There was a precipitous drop in the serum creatinine in the OKT3 group postoperatively. The control group patients who were on hemodialysis perioperatively had a similar pattern of renal recovery as the OKT3 group. b a (18, 23). Barri et al from our institution further characterized various degrees of ARF after liver transplantation and found that even mild acute kidney injury (a rise in serum Cr of >0.5 mg/ dL) was associated with decreased patient and graft survival (7) . Th e risk of end-stage renal disease was signifi cantly increased with severe acute kidney injury (a rise in serum Cr of 50% above baseline to >2 mg/dL).
OKT3 was initially used in liver and kidney transplantation as an induction agent (24, 25) . Millis et al had initially suggested its use for renal preservation after liver transplant (26) . To our knowledge, ours is the only study outlining the longterm outcomes of OKT3 use for renal preservation. Because of the introduction of other immunosuppressive agents and the growing body of literature describing the association of OKT3 with recurrence of hepatitis C and posttransplant lymphoproliferative disorders, its popularity has declined. Also, the unfavorable side eff ect profi le (cytokine release syndrome) has contributed to the decline in its popularity. Contrary to these concerns, in our study, there was no increase in the risk of posttransplant lymphoproliferative disorders, death from hepatitis C recurrence, and de novo malignancies with the use of OKT3.
Higher infection rates were present in the OKT3 group, but this was not solely related to the use of the agent. What is more likely is that the patients in the OKT3 group were more critically ill, as evidenced by their higher MELD scores, longer intensive care unit stay, and more severe renal failure. It appears that there was a dose-dependent response of renal recovery in patients who received OKT3. Th e dose of OKT3 that afforded the best renal recovery was 35 to 50 mg, as the 45 to 50 mg range resulted in the best renal recovery in the fi rst month and the 35 to 40 mg range after the fi rst month.
Th is study has several limitations. Although the data are from a prospective research database, the study's retrospective design and a diff erence in patient groups make it diffi cult to draw defi nite conclusions. In addition, although there were general guidelines for starting and stopping OKT3, there was not complete consistency in the pattern of practice of OKT3 use among diff erent surgeons. Th ese decisions were made at the discretion of the transplant surgeons, which may have introduced bias. Th ese limitations refl ect the challenges that the transplant team faces in management of the complex liver transplant patients with ARF.
In summary, this study has outlined the long-term results of the use of OKT3 in liver transplant patients for renal preservation. Although the patients in the OKT3 group had worse renal function preoperatively, they experienced impressive renal recovery. Th e use of OKT3 in patients who required RRT allowed more critically ill patients to achieve long-term survival comparable to that of patients who were less critically ill. Th is benefi t was not evident in patients who did not require RRT. Among the patients who were on RRT after liver transplant, recovery from RRT was a major determining factor in achieving long-term survival. Th e use of OKT3 in this clinical setting was safe long term, in that it was not associated with any deleterious long-term eff ects on hepatitis C recurrence-related deaths or occurrence of posttransplant malignancies. 
